{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:15:47Z","timestamp":1781075747704,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019503","name":"Kaohsiung Municipal Ta-Tung Hospital","doi-asserted-by":"publisher","award":["KMTTH-112-R002"],"award-info":[{"award-number":["KMTTH-112-R002"]}],"id":[{"id":"10.13039\/100019503","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST108-2314-B-002-190-MY3"],"award-info":[{"award-number":["MOST108-2314-B-002-190-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST109-2314-B-037-085 -MY3"],"award-info":[{"award-number":["MOST109-2314-B-037-085 -MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["111-2314-B-002-151-MY3"],"award-info":[{"award-number":["111-2314-B-002-151-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["112-2314-B-037 -073 -MY3"],"award-info":[{"award-number":["112-2314-B-037 -073 -MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW109-CDC-C-114-000108"],"award-info":[{"award-number":["MOHW109-CDC-C-114-000108"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW110-CDC-C-114-000103"],"award-info":[{"award-number":["MOHW110-CDC-C-114-000103"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW108-CDC-C-114-000108"],"award-info":[{"award-number":["MOHW108-CDC-C-114-000108"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.cmi.2024.06.024","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T20:21:01Z","timestamp":1720642861000},"page":"1410-1417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial"],"prefix":"10.1016","volume":"30","author":[{"given":"Hung-Ling","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Rui","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Hsuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Liang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau-Chyun","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inn-Wen","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinn-Moon","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.06.024_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/aje\/152.3.247","article-title":"Lifetime risks, incubation period, and serial interval of tuberculosis","volume":"152","author":"Vynnycky","year":"2000","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cmi.2024.06.024_bib2","series-title":"WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment: module 1: prevention","year":"2020"},{"key":"10.1016\/j.cmi.2024.06.024_bib3","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","article-title":"Latent Mycobacterium tuberculosis infection","volume":"372","author":"Getahun","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2024.06.024_bib4","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.cmi.2024.06.024_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4046\/trd.2017.0052","article-title":"Treatment of latent tuberculosis infection and its clinical efficacy","volume":"81","author":"Kim","year":"2018","journal-title":"Tuberc Respir."},{"key":"10.1016\/j.cmi.2024.06.024_bib6","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.5588\/ijtld.14.0829","article-title":"Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI","volume":"19","author":"Bliven-Sizemore","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.cmi.2024.06.024_bib7","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2024.06.024_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02048-2019","article-title":"Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs","volume":"55","author":"Ronald","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2024.06.024_bib9","first-page":"1650","article-title":"Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cmi.2024.06.024_bib10","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/17512433.2017.1366311","article-title":"Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?","volume":"10","author":"Alfarisi","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.cmi.2024.06.024_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.tube.2018.05.013","article-title":"Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: a multicentre randomised controlled trial in Taiwan","volume":"111","author":"Sun","year":"2018","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.cmi.2024.06.024_bib12","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/cix505","article-title":"High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent Mycobacterium tuberculosis infection","volume":"65","author":"Sandul","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.024_bib13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.amepre.2018.04.030","article-title":"Isoniazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis","volume":"55","author":"Njie","year":"2018","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.cmi.2024.06.024_bib14","doi-asserted-by":"crossref","first-page":"e1064","DOI":"10.1093\/cid\/ciaa1741","article-title":"Impact of age on outcome of rifapentine-based weekly therapy for latent tuberculosis infection","volume":"73","author":"Huang","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.024_bib15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/cid\/civ323","article-title":"Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study","volume":"61","author":"Sterling","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.024_bib16","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2024.06.024_bib17","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/cid\/ciad730","article-title":"Treatment responses to integrase strand-transfer inhibitor-containing antiretroviral regimens in combination with short-course rifapentine-based regimens for latent tuberculosis infection among people with HIV","volume":"78","author":"Lin","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.024_bib19","doi-asserted-by":"crossref","first-page":"e1252","DOI":"10.1093\/cid\/ciab209","article-title":"Completion rate and safety of programmatic screening and treatment for latent tuberculosis infection in elderly patients with poorly controlled diabetic mellitus: a prospective multicenter study","volume":"73","author":"Huang","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.024_bib20","first-page":"812","article-title":"Isoniazid concentration and NAT2 genotype predict risk of systemic drug reactions during 3HP for LTBI","volume":"8","author":"Lee","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.cmi.2024.06.024_bib21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A\u00a0method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.cmi.2024.06.024_bib22","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1136\/thorax.55.suppl_2.S61","article-title":"Allergic reactions to drugs: involvement of T cells","volume":"55","author":"Pichler","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.cmi.2024.06.024_bib23","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1046\/j.1365-2222.2000.00847.x","article-title":"Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions","volume":"30","author":"Yawalkar","year":"2000","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.cmi.2024.06.024_bib24","doi-asserted-by":"crossref","first-page":"e7430","DOI":"10.1097\/MD.0000000000007430","article-title":"The investigation of CD4+T-cell functions in primary HIV infection with antiretroviral therapy","volume":"96","author":"Sun","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.cmi.2024.06.024_bib25","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1164\/rccm.201912-2489OC","article-title":"Rifapentine population pharmacokinetics and dosing recommendations for latent tuberculosis infection","volume":"202","author":"Hibma","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2024.06.024_bib26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40615-015-0101-3","article-title":"Racial and ethnic disparities in adverse drug events: a systematic review of the literature","volume":"2","author":"Baehr","year":"2015","journal-title":"J\u00a0Racial Ethn Health Disparities"},{"key":"10.1016\/j.cmi.2024.06.024_bib27","article-title":"Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda","volume":"23","author":"Ferguson","year":"2020","journal-title":"J\u00a0Int AIDS Soc."},{"key":"10.1016\/j.cmi.2024.06.024_bib28","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1001\/jamainternmed.2017.3941","article-title":"Cost-effectiveness of testing and treatment for latent tuberculosis infection in residents born outside the United States with and without medical comorbidities in a simulation model","volume":"177","author":"Tasillo","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2024.06.024_bib29","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial","volume":"167","author":"Belknap","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2024.06.024_bib30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2125.2006.02746.x","article-title":"Patient reporting of suspected adverse drug reactions: a review of published literature and international experience","volume":"63","author":"Blenkinsopp","year":"2007","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24003045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24003045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:24:08Z","timestamp":1778592248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24003045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1198743X24003045"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.06.024","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.07.021","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.08.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.08.024","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}